title: Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.
abstract: We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2/day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.
authors.affiliation: Northwestern University, Chicago, Illinois.
authors.forename: L J
authors.initials: LJ
authors.lastname: Kilton
authors.forename: A B
authors.initials: AB
authors.lastname: Benson
authors.forename: A
authors.initials: A
authors.lastname: Greenberg
authors.forename: P
authors.initials: P
authors.lastname: Johnson
authors.forename: C
authors.initials: C
authors.lastname: Shapiro
authors.forename: R
authors.initials: R
authors.lastname: Blough
authors.forename: S
authors.initials: S
authors.lastname: French
authors.forename: L
authors.initials: L
authors.lastname: Weidner
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate